Jazz Pharmaceuticals (JAZZ): Handicapping Vyxeos - Bernstein

Bernstein analyst, Ronny Gal, reiterated his Market Perform rating on shares of Jazz Pharmaceuticals (NASDAQ: JAZZ) and raised the price target to $176 noting that AML drug, Vyxeos, was recently submitted to FDA with expected approval in the next 3-6 months.

The analyst sees see the size of the primary target population as ~4K per year, and based on 60% peak penetration and $120K price (high vs. classic chemo, but at lower band of novel therapeutics), estimates peak sales reaching $603M by 2025.

The new PT of $176 is up from $160.

For an analyst ratings summary and ratings history on Jazz Pharmaceuticals click here. For more ratings news on Jazz Pharmaceuticals click here.

Shares of Jazz Pharmaceuticals closed at $149.15 yesterday.

You May Also Be Interested In

• Freedom Broker Upgrades JPMorgan (JPM) to Buy, 'Greater Upside Potential'
• Microsoft (MSFT) PT Raised to $675 at UBS as 'Valuation Multiple Is Not Stretched'
• KION Group AG (KGX:GR) (KIGRY) PT Lowered to EUR52 at Deutsche Bank